Alzheimer's disease (AD) is the most common cause of dementia, accounting for 60% to 80% of the dementia cases. Unlike other leading causes of death, such as heart diseases and stroke that are steadily declining, the incidence rate of dementia is increasing. It's estimated that in 2050 there will be over 150 million dementia patients across the globe. This would put an immense pressure on the healthcare and social systems and lower the quality of life for a large population of older adults. The most prominent cognitive deficit caused by AD is a progressive deterioration of cognitive abilities, including working and, long-term episodic memory. These impairments result in a wide range of devastating problems for patients ranging from difficulties completing simple everyday tasks to a complete loss of independent living. Current therapies alleviate some of the symptoms but do not halt or reverse the progressive deterioration of high-order cognitive abilities. Search for effective therapies is urgent. An increasing number of studies investigating novel therapeutic approaches are focusing on measuring memory performance as the primary outcome. The aim of this research topic is to provide a comprehensive overview of the novel therapeutic approaches targeted at preventing memory loss in AD. As the brain abnormalities underlying memory deficits in AD are complex and multifactorial, we encourage submissions investigating a wide range of therapeutic targets in patients and animal models, including, but not limited to:
· preventing and reversing amyloid beta and neurofibrillary tangles accumulation
· synaptic abnormalities
· neuronal degeneration
· oxidative stress
· neural networks changes
· metabolism
· neuroinflammation
· brain stimulation
· neuroprotective agents
· neurogenesis
· microglia function
· autoimmunity
Regardless of the underlying mechanisms targeted, studies should include memory performance evaluation.
Alzheimer's disease (AD) is the most common cause of dementia, accounting for 60% to 80% of the dementia cases. Unlike other leading causes of death, such as heart diseases and stroke that are steadily declining, the incidence rate of dementia is increasing. It's estimated that in 2050 there will be over 150 million dementia patients across the globe. This would put an immense pressure on the healthcare and social systems and lower the quality of life for a large population of older adults. The most prominent cognitive deficit caused by AD is a progressive deterioration of cognitive abilities, including working and, long-term episodic memory. These impairments result in a wide range of devastating problems for patients ranging from difficulties completing simple everyday tasks to a complete loss of independent living. Current therapies alleviate some of the symptoms but do not halt or reverse the progressive deterioration of high-order cognitive abilities. Search for effective therapies is urgent. An increasing number of studies investigating novel therapeutic approaches are focusing on measuring memory performance as the primary outcome. The aim of this research topic is to provide a comprehensive overview of the novel therapeutic approaches targeted at preventing memory loss in AD. As the brain abnormalities underlying memory deficits in AD are complex and multifactorial, we encourage submissions investigating a wide range of therapeutic targets in patients and animal models, including, but not limited to:
· preventing and reversing amyloid beta and neurofibrillary tangles accumulation
· synaptic abnormalities
· neuronal degeneration
· oxidative stress
· neural networks changes
· metabolism
· neuroinflammation
· brain stimulation
· neuroprotective agents
· neurogenesis
· microglia function
· autoimmunity
Regardless of the underlying mechanisms targeted, studies should include memory performance evaluation.
